Human telomerase RNA expression and MIB-1 (Ki-67) proliferation index distinguish hemangioblastomas from metastatic renal cell carcinomas

Journal of Neuropathology and Experimental Neurology

Volumn 56, Issue 12, 1997, Pages 1349-1355

  Brown, Daniel F ^a   Gazdar, Adi F ^a   White III, Charles L ^a   Yashima, Kazuo ^a   Shay, Jerry W ^a   Rushing, Elisabeth J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Hemangioblastoma; Metastatic renal cell carcinoma; MIB 1; Telomerase expression

Indexed keywords

EPITHELIAL MEMBRANE ANTIGEN; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; RNA; TELOMERASE;

ADOLESCENT; ADULT; AGED; CANCER CLASSIFICATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMANGIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KIDNEY CARCINOMA; LABELING INDEX; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH;

EID: 0031440010     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199712000-00009     Document Type: Review

References (51)

1. Russell DS, Rubinstein LJ. Pathology of tumors of the nervous system. 5th ed. Baltimore: Williams and Wilkins; 1989:639-57
2. Burger PC, Scheitauer BW, Vogel FS. Surgical pathology of the nervous system and its coverings. 3rd ed. New York: Churchill Livingstone; 1991:373-88
3. Mondkar VP, Mckissock W, Russell RW. Cerebellar haemangioblastomas. Brit J Surg 1967;54:45-49
4. Constans JP, Meder F, Maiuri F, Donzelli R, Spaziante R, de Divititis E. Posterior fossa hemangioblastomas. Surg Neurol 1986;25: 269-75
5. Jurco S, Nadji M, Harvey DG, Parker JC Jr, Font RL, Morales AR. Hemangioblastomas: histogenesis of stromal cells studied by immunohistochemistry. Hum Pathol 1982;13:13-18
6. Tanimura A, Nakamura Y, Hachisuka H, Tanimura Y, Fukumura A. Hemangioblastoma of the central nervous system: Nature of the stromal cells as studied by the immunoperoxidase technique. Hum Pathol 1984;15:866-69
7. Kamitani H, Masuzawa H, Sato J, Kanazawa I. Capillary haemangioblastoma: Histogenesis of stromal cells. Acta Neuropathol 1987; 73:370-78
8. Yamashita J, Handa H, Kim C, Kim S. Familial occurrence of cerebellar hemangioblastomas - analysis of five families. Neurosurgery 1982;11:761-63
9. Neumann HPH, Eggert HR, Weigel K, Friedberg H, Wiestler OD, Schollmyer P. Hemangioblastomas of the central nervous system. J Neurosurg 1989;70:24-30
10. Andrew SM, Gradwell E. Immunoperoxidase labeled antibody staining in differential diagnosis of central nervous system haemangioblastomas and central nervous system metastases of renal carcinomas. J Clin Pathol 1986;39:917-19
11. Frank TS, Trojanowski JQ, Roberts SA, Brooks JJ. A detailed immunohistochemical analysis of cerebellar hemangioblastoma: An undifferentiated mesenchymal tumor. Mod Pathol 1989;2:638-51
12. Hufnagel TJ, Kim JH, True LD, Manuelidis EE. Immunohistochemistry of capillary hemangioblastoma: Immunoperoxidase-labeled antibody staining resolves the differential diagnosis with metastatic renal cell carcinoma, but does not explain the histogenesis of the capillary hemangioblastoma. Am J Surg Pathol 1989;13:207-16
13. Mills SE, Ross GW, Perentes E, Nakayawa Y, Scheitauer BW. Cerebellar hemangioblastoma: Immunohistochemical distinction from metastatic renal cell carcinoma. Surg Pathol 1990;3:121-32
14. Kaplan C, Sayre GP, Greene LF. Bilateral nephrogenic carcinomas in Lindau-von Hippel disease. J Urol 1961;86:36-42
15. Malek RS, Omess PJ, Benson RC, Zince H. Renal cell carcinoma in von Hippel-Lindau syndrome. Am J Med 1987;82:236-38
16. Stornes I, Jorgensen TM. Renal malignancy in von Hippel-Lindau's disease. Scand J Urol Nephrol 1993;27:139-42
17. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20
18. Gerdes J, Lemke H, Baisch H, Wacker H-H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-15
19. Schwarting R, Gerdes J, Niehus J, Jaeschke J, Stein H. Determination of the growth fraction in cell suspensions by flow cytometry using the monoclonal antibody Ki-67. J Immunol Methods 1986; 90:65-70
20. Sasaki K, Murakami T, Kawasaki M, Takahashi M. The cell cycle associated change of Ki-67 reactive nuclear antigen expression. J Cell Physiol 1987;133:579-84
21. Guillaud P, du Manoir S, Seigneurin D. Quantification and topographical description of Ki-67 antibody labeling during the cell cycle of normal fibroblastic (MRC-5) and mammary tumour cell lines (MCF-7). Anal Cell Pathol 1989;1:25-39
22. Verheijen R, Kuijpers HJH, van Driel R. Ki-67 detects a nuclear matrix-associated proliferation-related antigen. II. Localization in mitotic cells and association with chromosomes. J Cell Sci 1989; 92:531-40
23. Brown DC, Gatter KC. Monoclonal antibody Ki-67: Its use in histopathology. Histopathology 1990;17:489-503
24. Cattoretti G, Becker MHG, Key G, Duchrow M, Schluter C, Galle J, Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168:3573-63
25. Cuevas E, Jones DB, Wright DH. Immunohistochemical detection of growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol 1993;169:477-78
26. Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T. Ki-67 immunoreactivity in human central nervous system tumors: A study with MIB 1 monoclonal antibody on archival material. Acta Neuropathol 1994;87:47-54
27. Wakimoto H, Aoyagi M, Nakayama T, Nagashima G, Yamamoto S, Tamaki M, Hirakawa K. Prognostic significance of Ki-67 labeling indices obtained using MIB-I monoclonal antibody in patients with supratentorial astrocytomas. Cancer 1996;77:373-80
28. Kros JM, Hop WCJ, Godschalk JJCJ, Krishnadath KK. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 1996;78:1107-13
29. Matsuno A, Fujimaki T, Sasaki T, et al. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas. Acta Neuropathol 1996;91:504-10
30. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345:458-60
31. Counter CM, Avilion AA, Lefeuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992;11:1921-29
32. Biessmann H, Mason JM. Genetics and molecular biology of telomeres. Adv Gen 1992;30:185-249
33. Shippen DE. Telomeres and telomerases. Curr Opin Gen Dev 1993; 3:759-63
34. Counter CM, Hirte HW, Bacchetti S, Harley CB. Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA 1994; 91:2900-2904
35. de Lange T. Activation of telomerase in a human tumor. Proc Natl Acad Sci USA 1994;91:2882-85
36. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-15
37. Harley CB, Villeponteau B. Telomeres and telomerase in aging and cancer. Curr Opin Gen Dev 1995;5:249-55
38. Langford LA, Piatyszek MA, Xu R, Schold SC, Shay JW. Telomerase activity in human brain tumors. Lancet 1995;346:1267-68
39. DeMasters BKK, Markham N, Lillehei K, Shroyer KR. Differential telomerase expression in human primary intracranial tumors. Am J Clin Pathol 1997;107:548-54
40. Langford L, Piatyszek MA, Ruishu X, Schold SC, Wright WE, Shay JW. Telomerase activity: A prognostic indicator in ordinary meningiomas. Hum Pathol 1997;28:416-20
41. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995;1:249-55
42. Hiyama K, Hiyama E, Ishioka S, et al. Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 1995;87: 895-901
43. Hiyama E, Yokoyama T, Tatsumoto N, et al. Telomerase activity in gastric cancer. Cancer Res 1995;55:3258-62
44. Mehle C, Piatyszek MA, Ljungberg B, Shay JW, Roos G. Telomerase activity in human renal cell carcinoma. Oncogene 1996;13: 161-66
45. Yashima K, Piatyszek MA, Saboorian HM, Virmani AK, Brown D, Shay JW, Gazdar AF. Telomerase activity and in situ telomerase RNA expression in malignant and non-malignant lymph nodes. J Clin Pathol 1997;50:110-17
46. Feng J, Funk WD, Wang S-S et al. The RNA component of human telomerase. Science 1995;269:1236-41
47. Delahunt B, Bethwaite PB, Thornton A, Ribas JL. Proliferation of renal cell carcinoma assessed by fixation-resistant polyclonal Ki-67 antibody labeling: Correlation with clinical outcome. Cancer 1995; 75:2714-19
48. Tannapfel A, Hahn HA, Katalinic A, Fietkau RJ, Kuhn R, Wittekind CW. Prognostic value of ploidy and proliferation markers in renal cell carcinoma. Cancer 1996;77:164-71
49. Haitel A, Wiener HG, Migschitz B, Marberger M, Susani M. Proliferating cell nuclear antigen and MIB-1: An alternative to classic prognostic indicators in renal cell carcinomas? Am J Clin Pathol 1997;107:229-35
50. Piatyszek MA, Kim NW, Weinrich SL, Hiyama K, Hiyama E, Wright WE, Shay JW. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci 1995;17:1-15
51. Wright WE, Shay JW, Piatyszek MA. Modification of a telomeric repeat amplification protocol (TRAP) results in increased reliability, linearity, and sensitivity. Nucleic Acids Res 1995;23:3794-95